Resonance Specialties Limited
Regd. Office: Plot No. 54-D, Kandivli Industrial Estate, Kandivali (W) Mumbai - 400067, India
Tel: +91-22-6857 2827/6210 6053 **Fax:** +91-22-28688544 **E-mail**-info@resonancesl.com
Website : www.resonancesl.com **CIN:** L25209MH1989PLCO51993 GST:27AAACA9590Q1ZW

THRU ONLINE FILING

August 4, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code - 524218

Sub: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held today at Mumbai have approved the following.

A. Unaudited Financial Results for the 1st Quarter ended June 30, 2026 along with Limited Review Report by the Auditors on the Unaudited Financial Results; and

B. Purchase of manufacturing facility situated at Plot No. 6, New Industrial Area-II, Mandideep, Dist Raisen- 462046, Madhya Pradesh along with leasehold land, buildings, plant & machineries, licenses, permits, along with employees, etc. from Kaygee Laboratories Private Limited ("KLPL") a related party, for a consideration of Rs. 29.98 crores on slump sale basis, subject to the approval of the shareholders [Brief description of this manufacturing unit provided in the Annexure].

Kindly note that the Board meeting commenced at 11:00 a.m. and concluded at 12.05 p.m.

Thanking you,
Yours faithfully
For Resonance Specialties Limited

VAIBHAVI PRUTHVI SHAH

Vaibhavi Shah
Company Secretary
ACS:72229
Encl.: a/a

Annexure

The summary of the proposed transaction for the purchase of the manufacturing unit being and situated at Mandideep (Madhya Pradesh) from Kaygee Laboratories Pvt. Ltd., a related party is tabulated below :

1.	Manufacturing unit /facility proposed to be purchased	Purchase of manufacturing unit being and situated at Plot No. 6, New Industrial Area - II, Mandideep, Dist. Raisen - 462046, Madhya Pradesh consisting of leasehold land admeasuring about 22,304 sq. mtrs. together with industrial buildings of about 5,227 sq. mtrs. standing thereon together with plant & machineries, licenses, permits, permissions and employees employed at the said manufacturing unit, etc. on a slump sale basis, subject to the approval of the shareholders.
2.	Date on which the agreement for purchase has been entered into	The agreement will be entered into in due course of time subject to necessary consent.
3.	The expected date of completion of purchase	On or before 30th November, 2026 or such other date as may be mutually agreed subject to the necessary consents for the transfer of the leasehold rights on the land on which this manufacturing unit is situated.
4.	Consideration payable for such purchase	Rs. 29.98 crores.
5.	Brief details of sellers and whether the seller belong to the promoter/ promoter group/ group companies. If yes, details thereof;	The seller is M/s. Kaygee Laboratories Private Limited, a promoter group company. Kaygee Laboratories Private Limited holds 14.35% of the equity share capital of Makers Laboratories Limited, which, in turn, holds 45.48% of the equity share capital of the Company. Kaygee Investments Private Limited, another company, belonging to the same promoter group also holds 8.77% of the equity share capital of the Company.

Resonance Specialties Limited
Regd. Office: Plot No. 54-D, Kandivli Industrial Estate, Kandivali (W) Mumbai - 400067, India
Tel: +91-22-6857 2827/6210 6053 **Fax:** +91-22-28688544 **E-mail**-info@resonancesl.com
Website : www.resonancesl.com **CIN:** L25209MH1989PLCO51993 GST:27AAACA9590Q1ZW

6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Yes. This transaction will fall within the purview of related party transactions and is done at an arm's length basis based on valuation certificate issued by an Independent Registered valuer.
7.	Whether the purchase of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	The proposed purchase of the undertaking is outside the scheme of arrangement.
8.	Area of business of the entity(ies)	The Company is engaged in the development, manufacturing, marketing and distribution of specialty chemicals / APIs. M/s. Kaygee Laboratories Private Ltd. is engaged in the business of development, manufacturing of chemical intermediates and APIs.
9.	Rationale for purchase of undertaking	The manufacturing unit proposed to be acquired was originally set-up in the year 1990 by M/s. Vista Organics Private Limited, a company incorporated by the erstwhile promoters of the Company. Since this manufacturing unit was set-up, it was manufacturing and supplying on an exclusive basis chemical intermediates as well as certain APIs manufactured at the said manufacturing unit to the Company on a job work basis. The products so manufactured were such products for which the Company was not having capability, manufacturing facility or technology to manufacture such products. The manufacturing unit proposed to be acquired is recently inspected and approved by WHO, Geneva. This manufacturing unit manufactures Company's required Chemical Intermediates and APIs under conversion agreement. Raw materials are provided by the Company and the Unit manufactures finished goods and then it is supplied to Company primarily to manufacture Company's end products. Accordingly, it would be beneficial for the Company to acquire and own this manufacturing facility,

		thereby securing uninterrupted production facility, enhancing operational control and efficiency and eliminating the additional costs associated with outsourcing of the manufacturing activities for chemical intermediates as well as APIs required by the Company. The proposed transaction is neither prejudicial to the interests of the public shareholders non discriminatory in nature and is in the best interest of the Company.
10.	In case of cash consideration – amount or otherwise share exchange ratio	Cash consideration of Rs. 29.98 crores.
11.	Brief details of change in shareholding pattern (if any) of listed entity	There will not be any change in the shareholding pattern of the Company due to this sale of manufacturing facility.

KAILASH CHAND JAIN & CO. (Regd.)

CHARTERED ACCOUNTANTS

EDENA, 1st Floor,
97, Maharshi Karve Road,
Near Income Tax Office,
Mumbai - 400 020.
e-mail : mail@kcjainco.com

Phone : 022-22009131
022-22005373
022-22065373

Independent Auditor's Review Report On the Quarterly unaudited financial results of Resonance Specialties Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Resonance Specialties Limited

1. We have reviewed the accompanying statement of Unaudited Financial Results of **Resonance Specialties Limited** (the 'Company') for the quarter ended June 30, 2026 attached herewith being submitted by the Company pursuant to requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS-34) "Interim Financial Reporting" prescribed under section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in Accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquire of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kailash Chand Jain & Co.
Chartered Accountants
Firm Registration No.: 112318W

Saurabh Chouhan

Saurabh Chouhan
Partner
Membership No.: 167453
Date: August 04, 2026
Place: Mumbai
UDIN: 26167453XBAMPL2254

KAILASH CHAND JAIN & CO.
MUMBAI
FRN:112318W
Chartered Accountants

Branches: Delhi • Kolkata • Indore • Bhopal • Raipur

Resonance Specialties

RESONANCE SPECIALTIES LIMITED

REGD. OFFICE: 54-D, Kandivali Industrial Estate, Charkop, Kandivali (West) MUMBAI 67, Website: www.resonancesl.com

(CIN No. L25209MH1989PLC051993)

TEL: 022 6857 2827 Email: company.secretary@resonancesl.com Website: www.resonacesl.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

(₹ In Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Year Ended
		June 30, 2026 (Unaudited)	March 31, 2026 (Audited)*	June 30, 2025 (Unaudited)	March 31, 2026 (Audited)
I	Revenue from operations	3,258.41	2,447.71	2,127.42	9,024.75
II	Other Income	53.78	73.63	22.71	164.18
III	**Total Income (I+II)**	**3,312.19**	**2,521.34**	**2,150.13**	**9,188.93**
IV	**Expenses**				
	(a) Cost of material consumed	1,360.36	998.73	654.97	3,907.06
	(b) Conversion Charges	332.13	460.44	278.61	1,677.91
	(c) Changes in inventories of finished goods, Stock-in -Trade and working-progress	221.46	(114.26)	526.04	48.49
	(d) Employee Benefits Expense	161.93	164.04	141.96	589.66
	(e) Depreciation and amortization expenses	33.82	34.25	32.64	133.57
	(f) Finance costs	1.27	4.68	7.87	24.05
	(g) Other expenses	436.29	374.30	270.80	1,400.84
	Total Expenses (IV)	**2,547.26**	**1,922.18**	**1,912.89**	**7,781.58**
V	**Profit / (Loss) before exceptional items and tax (III-IV)**	**764.93**	**599.16**	**237.24**	**1,407.35**
VI	Exceptional Items (Income)/Expense	-	-	-	-
VII	**Profit/ (loss) before tax (V-VI)**	**764.93**	**599.16**	**237.24**	**1,407.35**
VIII	Tax Expenses				
	- Current tax	199.96	155.67	60.35	353.40
	- Short/(Excess) provision of earlier years taxes	-	(15.17)	10.78	(4.39)
	- Deferred tax liability/(asset)	(9.45)	(0.90)	3.07	18.76
IX	**Profit/(loss) for the period (VII-VIII)**	**574.42**	**459.56**	**163.04**	**1,039.58**
X	Other Comprehensive Income				
	A. Items that will not be reclassified to profit or loss				
	Actuarial Gain/(Loss)	0.05	4.32	0.16	(3.43)
	Tax exffects thereon	(0.01)	(1.12)	(0.04)	0.89
		0.04	**3.20**	**0.12**	**(2.54)**
	B. Items that will be reclassified to profit or loss	-	-	-	-
	Tax exffects thereon	-	-	-	-
		-	-	-	-
	Other Comprehensive Income/ (Loss) for the period net of tax (X)	**0.04**	**3.20**	**0.12**	**(2.54)**
XI	**Total Comprehensive Income (Net Profit / (Loss) for the year / period (IX+X)**	**574.46**	**462.76**	**163.16**	**1,037.04**
XII	Paid up Equity Share Capital (face value ₹ 10/- each)	1,154.40	1,154.40	1,154.40	1,154.40
XIII	Other Equity				5,802.75
XIV	Net Worth				7,323.77
XV	Earnings per equity share (of ₹ 10/- each)) (Not annualized)				
	(1) Basic (₹)	4.98	3.98	1.41	9.01
	(2) Diluted (₹)	4.98	3.98	1.41	9.01

RESONANCE SPECIALTIES LIMITED MUMBAI

KAILASH CHAND JAIN & CO. MUMBAI FRN:112318W Chartered Accountants

Notes:

1. The financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standard) Rules' 2015 (IND-AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
2. The above results have been reviewed by the audit committee and thereafter approved by the Board of Directors in their meeting held on 4th August 2026.
3. In accordance with Ind AS-108 "Operating Segments", the company has only one reportable primary business segment i.e. "Chemical Manufacturing". However, the company has secondary geographical segment which is disclosed in the financial statement as per Ind AS-108.

   Information about secondary geographical segments as per financial statements

   (Rs. In Lakhs)

Particulars	**April to June, 2026**	**April to June, 2025**
Segment Revenue		
- India	932.33	1,061.93
- Outside India	2,326.08	1,065.49
Total	**3,258.41**	**2,127.42**

   The segment asset and segment capital expenditure attributable to the segment "Outside India" is less than 10% of the respective total assets and total capital expenditure and therefore not disclosed separately.

4. As at 30th June, 2026 the company does not have any subsidiary/associate/Joint venture company (IES).
5. *The figures of the quarter ended 31st March 2026 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and published unaudited year –to- date figures up to the third quarter ended December 31, 2025 which were subjected to limited review.
6. The figures for the previous financial period have been regrouped/rearranged wherever necessary.

By the order of the Board
For RESONANCE SPECIALTIES LIMITTED

RESONANCE SPECIALTIES LIMITED MUMBAI

KAILASH CHAND JAIN & CO. MUMBAI FRN:112318W Chartered Accountants

Charchit Jain
Whole Time Director
DIN: 09344495
Place: Mumbai
Date: 04th August, 2026